Medical marijuana for management of cancer pain: a narrative review.
Narrative review examines medical marijuana efficacy for cancer pain management across 40 US states with legal access.
This narrative review consolidates recent evidence on medical marijuana use for cancer pain across the expanding legal landscape in the US. The systematic approach to literature synthesis helps clarify current understanding of cannabis efficacy and usage patterns in oncology pain management.
With 40 states now permitting medical marijuana, oncologists and pain specialists need evidence-based guidance on cannabis integration into cancer care. This review addresses the growing clinical need for synthesized data on marijuana’s role in comprehensive cancer pain management strategies.
| Study Type | Narrative Review |
| Population | Cancer patients using medical marijuana for pain management |
| Intervention | Medical marijuana/cannabis products |
| Comparator | Not applicable for narrative review |
| Primary Outcome | Prevalence and efficacy of marijuana use for cancer-related pain |
| Key Finding | Review synthesis of cannabis use patterns and effectiveness in cancer pain (specific results not provided in abstract) |
| Journal | Annals of Palliative Medicine |
| Year | 2025 |
The review provides a structured examination of medical marijuana’s role in cancer pain management within the current legal framework. However, without access to the full synthesis results, specific clinical recommendations cannot be extracted from this abstract alone.
The abstract does not present the actual findings, effect sizes, or specific recommendations from the reviewed literature. It cannot establish causation, optimal dosing protocols, or comparative effectiveness against standard cancer pain treatments.
Narrative reviews lack the systematic methodology of meta-analyses and may be subject to selection bias in included studies. The variability in cannabis products, dosing, and patient populations across reviewed studies likely limits generalizable conclusions.
This review represents an attempt to systematically examine cannabis use in cancer pain management within the current US legal framework. The clinical value depends entirely on the quality of the synthesis and specific findings, which are not available in this abstract.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Is medical marijuana legal for cancer pain management in the United States?
Yes, medical marijuana is currently legal in 40 states and the District of Columbia. This widespread legalization has increased clinical interest in its application for managing cancer-related pain, though regulations and access vary by state.
This narrative review examined the efficacy of medical marijuana for cancer pain management, though specific efficacy data would need to be extracted from the individual studies analyzed. The review focuses on understanding both the therapeutic effects and the variability in patient responses to cannabis-based treatments.
What types of cannabinoids are being studied for cancer pain relief?
The research encompasses various cannabinoids including THC (tetrahydrocannabinol) and CBD (cannabidiol), as well as broader medical cannabis formulations. These different compounds may have varying effects on pain pathways and patient outcomes in oncology settings.
Why do patients respond differently to medical marijuana for cancer pain?
Patient response variability remains a key area of investigation in cannabis research. Factors contributing to different responses may include individual pain pathway differences, cancer type, dosing protocols, and genetic variations in cannabinoid metabolism, though more research is needed to fully understand these mechanisms.
What should oncologists know about prescribing medical marijuana for cancer patients?
Oncologists should be aware that while medical marijuana shows promise for cancer pain management, the evidence base is still developing. Understanding local legal requirements, potential drug interactions, and individual patient factors is essential before considering cannabis-based treatments as part of a comprehensive pain management strategy.
